Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Underexplored mutations in plasma cell myeloma

Kirti Arora, Diana Basali, Yasar Shad, Akriti Jain, Christy Samaras, Haleema Sadia Adil, Jason Valent, Louis Williams, Jack Khouri, Sandra Mazzoni, Faiz Anwer, Abhay Singh, Shahzad Raza

Blood (2025) 146 (Supplement 1): 4025.

https://doi.org/10.1182/blood-2025-4025

Published: 2025

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

Yulia Shifrin, Asieh Alikhah, Zahabiya Husain, Jack Khouri, Louis Williams, Christy Samaras, Shahzad Raza, Faiz Answer, Jason Valent, Beth Faiman, Emmet Samsa, Jessica Jones, Kelly Shepperd, Sabine Mai, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2025-2217

Published: 2025

Journal Articles

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Sandra Mazzoni, Babal Jha, Louis Williams, Jack Khouri, Christy Samaras, Shahzad Raza, Faiz Anwer, Jason Valent, Arda Durmaz, Yahan Zhang, Kacey O'Donnell

Blood (2025) 146 (Supplement 1): 7473.

https://doi.org/10.1182/blood-2025-7473

Published: 2025

Journal Articles

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Abhishek Kataria, Mikhaila Rice, Wei Wei, Faiz Anwer, Paolo Caimi, Allison Winter, Robert Dean, Taylor Brooks, Joslyn Rudoni, Jack Khouri, Christy Samaras, Shahzad Raza, Sandra Mazzoni, Jason Valent, Brian Hill, Deepa Jagadeesh

Blood (2025) 146 (Supplement 1): 2737.

https://doi.org/10.1182/blood-2025-2737

Published: 2025

Journal Articles

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Kirti Arora, Rishi Chowdhary, Diana Basali, Christy Samaras, Akriti Jain, Deevyashali Parekh, Jason Valent, Jack Khouri, Louis Williams, Sandra Mazzoni, Abhay Singh, Faiz Anwer, Shahzad Raza

Blood (2025) 146 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2025-2248

Published: 2025

Journal Articles

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Yahan Zhang, Sandra Mazzoni, Arda Durmaz, Kacey O'Donnell, Christy Samaras, Faiz Anwer, Shahzad Raza, Jason Valent, Jack Khouri, Louis Williams, Babal Jha

Blood (2025) 146 (Supplement 1): 7476.

https://doi.org/10.1182/blood-2025-7476

Published: 2025

Journal Articles

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Blood (2025) 146 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2025-3970

Published: 2025

Journal Articles

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Kristina Nasr, Yan Zou, Shahzad Raza, Mazen Hanna, Jack Khouri, Jason Valent, Christy Samaras, Sandra Mazzoni, Cynthia Scott, Kimberly Hamilton, Saveta Mathur, Beth Faiman, Louis Williams, Faiz Anwer, Diana Basali

Blood (2025) 146 (Supplement 1): 3969.

https://doi.org/10.1182/blood-2025-3969

Published: 2025

Journal Articles

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Vasil Mico, Raymond Comenzo, Shahzad Raza, Jason Valent, Faiz Anwer, Christy Samaras, Louis Williams, Jack Khouri, Xia Wu, Parva Bhatt, Andreas Klein, Joslyn Rudoni, Teresa Fogaren, Mikhaila Rice, Jonathan Kissam, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2025-3961

Published: 2025

Journal Articles

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Blood (2025) 146 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2025-4601

Published: 2025

Journal Articles

Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning

John Hanna, Ran Zhao, Diana Basali, Shahzad Raza, Jack Khouri, Sandra Mazzoni, Christy Samaras, Beth Faiman, Ali Mehdi, Mazen Hanna, Faiz Anwer, Jason Valent, Louis Williams

Blood (2025) 146 (Supplement 1): 5743.

https://doi.org/10.1182/blood-2025-5743

Published: 2025

Journal Articles

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Kelsey Pandrangi, Kristina Nasr, Sharan Jhaveri, Mikhaila Rice, Joslyn Rudoni, Louis Williams, Christy Samaras, John Molina, Betty K. Hamilton, Shahzad Raza, Faiz Anwer, Jason Valent, Claudio Brunstein, Brian Hill, Paolo Caimi, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 6376.

https://doi.org/10.1182/blood-2025-6376

Published: 2025

Journal Articles

Real-world outcomes with teclistamab in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective study using trinetx database

Deevyashali Parekh, Beth Faiman, Sandra Mazzoni, Louis Williams, Jack Khouri, Hossam M. Ali, Utkarsh Goel, Jason Valent, Diana Basali, Christy Samaras, Tara Roy, Alexandra McDonald, Faiz Anwer, Majid Jaberi, Kirti Arora, Haleema Sadia Adil, Julie Bevacqua, Rahul Seth, Shahzad Raza

Blood (2025) 146 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2025-6372

Published: 2025

Journal Articles

Talquetamab in Relapsed/Refractory multiple myeloma with renal impairment: A quaternary cancer center experience

Hossam M. Ali, Sandra Mazzoni, Utkarsh Goel, Jack Khouri, Faiz Anwer, Asfand Yar Cheema, Louis Williams, Diana Basali, Christy Samaras, Beth Faiman, Willem van Heeckeren, Kimberly Hamilton, Joslyn Rudoni, Mikhaila Rice, Jonathan Kissam, Cynthia Scott, Saveta Mathur, Jason Valent, Shahzad Raza

Blood (2025) 146 (Supplement 1): 6367.

https://doi.org/10.1182/blood-2025-6367

Published: 2025

Journal Articles

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Blood (2025) 146 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2025-6350

Published: 2025

Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Blood (2017) 130 (Supplement 1): 1888.

https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888

Published: 2017

Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Blood (2017) 130 (Supplement 1): 1811.

https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811

Published: 2017

Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1812.

https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812

Published: 2017

Journal Articles

Response-Adapted Therapy for Newly Diagnosed Myeloma

Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD, Mitchell R. Smith

Blood (2016) 128 (22): 3606.

https://doi.org/10.1182/blood.V128.22.3606.3606

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Underexplored mutations in plasma cell myeloma

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Real-world outcomes with teclistamab in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective study using trinetx database

Talquetamab in Relapsed/Refractory multiple myeloma with renal impairment: A quaternary cancer center experience

Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Response-Adapted Therapy for Newly Diagnosed Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only